The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score 4.61 — safe zoneOK
- Earnings-manipulation signal · Beneish M -2.21 — no flag raisedOK
- Earnings quality 91/100 — accruals in line with cashOK
Where the revenue comes from
Fiscal 2025, as Lantheus Holdings, Inc. reports it. History and quarterly detail are in the app.
- Product$1.5B
- Radiopharmaceutical Oncology$989.1M
- PYLARIFY$989.1M
- Total Precision Diagnostics$493.1M
- Definity$330.2M
Leadership changes
From Lantheus Holdings, Inc.'s own filings, the day they're filed.
- Andrea Sabens · Chief Accounting Officer · departureeff. 2024-07-01
- Kimberly Brown · Chief Accounting Officer · appointmenteff. 2024-07-01
- Julie McHugh · Director · appointmenteff. 2024-01-23
Latest filings
- 10-Q · Quarterly report2026-05-07
- 8-K · Company announcement2026-05-07
- 8-K · Company announcement2026-05-01
- DEF 14A · Annual proxy (pay & governance)2026-03-20
- 8-K · Company announcement2026-02-26
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, every figure source-linked🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask anything about Lantheus Holdings, Inc., every answer cited🔒
- The Intelligence Brief — added when Lantheus Holdings, Inc.'s brief passes our SEC-figure check🔒
Every figure links to the filing it came from, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.